Legacy mRNA Capping Methods Still in Use
mCAP Co-transcriptional
First-generation cap analog, yielding only 50% capping efficiency and a Cap 0 structure
Anti-Reverse Cap Analog (ARCA)
Co-transcriptional capping method that creates a Cap 0 structure with ~70% capping efficiency
Enzymatic Capping Post-transcriptional
Capping method that requires multiple reaction and purification steps
The Future of Capping is Here to Help
Get You to Market Faster
By modifying the structure of a traditional cap analog, we created CleanCap technology. The evolved cap analog produces a Cap 1 structure incorporated by RNA polymerase in a single in vitro transcription reaction to increase efficiency while reducing process time.
- Higher quality mRNA with 95% capping efficiency
- Higher transcriptional yield per mL
- Reduced immunogenicity due to the natural Cap 1 structure
- One-pot solution with fewer manufacturing steps
Patented in 2015 and cited in thousands of publications
Available in both research and GMP grade
Used in the production of >3 billion doses of COVID-19 vaccine
Tried and Trusted Technology
Used in global commercial manufacturing programs, including a leading COVID-19 vaccine, CleanCap technology has proven to be the optimal mRNA vaccine capping method. See how we ramped up production to meet unprecedented demands in the global pandemic. View case study >
Ready to Elevate Your mRNA Capping Process?
Talk to our team about what may be the best option for you. Fill out the form below to get started.
